Preclinical studies demonstrate sotrovimab retains activity against the full combination of mutations in the spike protein of the Omicron SARS-CoV-2 variant

New preclinical findings generated through in vitro testing of sotrovimab against the complete pseudo-virus, updated to bioRxiv